IL225581B - Defibrotide for use in prophylaxis and/or treatment of graft versus host disease (gvhd)

24 members in 10 offices

This recordMember, by publication datePriority claim

Priority claims
Document	Office	Kind	Date
2010000451	Italy	W	2010-11-12

Family members, oldest first
Document	Office	Kind
CA2813413A1	Canada	A1	2012-05-18
WO2012063272A1	World Intellectual Property Organization (WIPO)	A1	2012-05-18
AU2010363814A1	Australia	A1	2013-05-02
IL225581D0	Israel	D0	2013-06-27
AU2010363814A8	Australia	A8	2013-07-18
CN103260627A	China	A	2013-08-21
US2013231470A1	United States of America	A1	2013-09-05
EP2637672A1	European Patent Office (EPO)	A1	2013-09-18
JP2013545747A	Japan	A	2013-12-26
US8980862B2	United States of America	B2	2015-03-17
US2015297624A1	United States of America	A1	2015-10-22
AU2010363814B2	Australia	B2	2016-05-19
US9539277B2	United States of America	B2	2017-01-10
JP6069209B2	Japan	B2	2017-02-01
US2017080012A1	United States of America	A1	2017-03-23
CN107007617A	China	A	2017-08-04
US2017304349A1	United States of America	A1	2017-10-26
US9867843B2	United States of America	B2	2018-01-16
CA2813413C	Canada	C	2018-03-06
IL225581BThis record	Israel	B	2018-07-31
EP2637672B1	European Patent Office (EPO)	B1	2018-08-22
DK2637672T3	Denmark	T3	2018-10-22
ES2694239T3	Spain	T3	2018-12-19
US2021052622A1	United States of America	A1	2021-02-25

4 legal events, as the office reported them to INPADOC

Point at a mark for the event

English: Defibrotide for use in prophylaxis and/or treatment of graft versus host disease (gvhd)
Hebrew: דפיברוטייד לשימוש במניעה ו/או טיפול במחלת שתל נגד מארח (gvhd)

CPC, 8: A61K31/711
A61K31/7088
A61P37/06
A61P43/00
C12N15/11
C12N15/111
A61K9/0019
A61K9/08
Filled: the office’s first classification

Defibrotide for use in prophylaxis and/or treatment of graft versus host disease (gvhd)